New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareThymulin vs Prostamax

Thymulin vs Prostamax

Side-by-side comparison of key properties, dosing, and research.

Immune Support
Thymulin
Anti-Aging & Longevity
Prostamax
Summary
Thymulin is a nonapeptide hormone produced exclusively by the thymic epithelium. It requires zinc for biological activity and plays a critical role in T-lymphocyte maturation, differentiation, and immune regulation. Thymulin levels decline dramatically with age, contributing to immunosenescence.
Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
Half-Life
~30 minutes active half-life
Short (minutes); sustained gene-regulatory effects
Admin Route
SubQ
SubQ, Oral
Research
Typical Dose
20-30 mcg
10 mg per day
Frequency
10 days per month (Khavinson protocol)
Daily for 10–30 days
Key Benefits
  • Enhances T-cell maturation and differentiation
  • Boosts NK cell cytotoxic activity
  • Reduces inflammatory cytokine production (TNF-α, IL-1)
  • Anti-nociceptive (pain-reducing) properties
  • Restores age-related immune decline
  • Anti-inflammatory via serotonin pathway modulation
  • Supports normalization of prostate tissue architecture
  • May reduce prostate enlargement associated with BPH
  • Anti-inflammatory effects on prostatic tissue
  • Reduces prostate cell apoptosis from oxidative stress
  • Potential support in chronic prostatitis
  • Anti-aging effects on prostate glandular tissue
  • Complementary to conventional BPH therapies
Side Effects
  • Injection site reactions
  • Mild fatigue initially as immune system activates
  • Generally well tolerated in available research
  • Mild injection site reactions
  • No significant adverse urological events reported at standard doses
Stacks With